Cancer Genetics (CGIX) Reports In-Line Q2 EPS

Cancer Genetics (NASDAQ: CGIX) reported Q2 EPS of ($0.51), in-line with the analyst estimate of ($0.51). Revenue for the quarter came in at $4.2 million versus the consensus estimate of $4.67 million.

For earnings history and earnings-related data on Cancer Genetics (CGIX) click here.

You May Also Be Interested In

• Investing.com’s stocks of the week
• ITC Ltd. (ITC:IN) PT Lowered to INR310 at JPMorgan
• Home Federal Bancorp of Louisiana (HFBL) Tops Q2 EPS by 46c